Table 2.

Risk of Cancer Associated with BMP Administration in Unadjusted and Adjusted Models

	Crude Hazard Ratio			Adjusted Hazard Ratio
	HR	95%CI		HR	95%CI
Diagnosis in Follow Up
Any Cancer	0.98	0.95	1.02	0.99	0.96	1.03
Bone	0.76	0.59	1.00	0.77	0.59	1.01
Brain	0.83	0.66	1.03	0.82	0.66	1.03
Breast	1.05	0.96	1.15	1.05	0.95	1.15
Cervix Uteri	0.91	0.61	1.34	0.91	0.61	1.34
Colon and Rectum	0.99	0.88	1.11	1.00	0.89	1.12
Corpus Uteri	0.84	0.64	1.10	0.85	0.64	1.11
Esophagus	0.98	0.71	1.37	1.00	0.72	1.39
Hodgkins Lymphoma	1.09	0.96	1.25	1.10	0.97	1.26
Non Hodgkins Lymphoma	1.01	0.93	1.10	1.02	0.94	1.11
Kaposi Sarcoma	0.67	0.24	1.87	0.67	0.24	1.87
Kidney and Renal Pelvis	1.01	0.85	1.20	1.02	0.86	1.21
Larynx	0.89	0.58	1.35	0.90	0.59	1.37
Leukemia	1.06	0.88	1.28	1.08	0.90	1.30
Liver and Intrahepatic Bile Ducts	1.15	0.94	1.41	1.17	0.95	1.43
Lung and Bronchus	0.96	0.87	1.06	0.96	0.87	1.07
Melanoma	1.06	0.94	1.20	1.09	0.96	1.22
Mesothelioma	0.95	0.58	1.54	0.96	0.59	1.56
Myeloma	0.90	0.76	1.07	0.91	0.76	1.08
Oral cavity and Pharynx	0.92	0.59	1.45	0.94	0.60	1.48
Ovary	1.10	0.89	1.37	1.10	0.89	1.37
Pancreas	1.10	0.74	1.62	1.11	0.75	1.64
Prostate	0.95	0.87	1.05	0.96	0.87	1.05
Stomach	1.06	0.80	1.41	1.08	0.81	1.43
Testis	1.18	0.60	2.32	1.17	0.60	2.30
Thyroid	1.14	0.86	1.52	1.12	0.84	1.48
Urinary bladder	0.96	0.83	1.12	0.99	0.85	1.15